力生製藥(002393.SZ):2024年淨利潤1.85億元 同比下降49%
格隆匯3月20日丨力生製藥(002393.SZ)公佈2024年年度報吿,合併口徑實現營業收入13.36億元,較上年增長15.88%。利潤總額2.16億元,較上年下降48.61%。淨利潤1.85億元,較上年下降49%,上年度公司處置土地產生收益23,844.22萬元,同期剔除該因素後,本年度利潤總額同比增長18.80%。本年度公司調整營銷模式,理順產品價值鏈,收回核心產品總經銷權,當期成本費用有所增加,導致公司扣除非經常性損益後的歸屬於上市公司股東的淨利潤1.03億元,同比下降31.16%。資產總額57.86億元,較上年末增長0.08%,歸屬於上市公司股東的淨資產47.70億元,較上年末下降2.72%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.